Cargando…
Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma
Pleomorphic adenoma (PA) is the most common salivary gland neoplasm and, although mostly benign, recurrences, being called recurrent pleomorphic adenoma (RPA) and malignant transformation to carcinoma ex pleomorphic adenoma (CXPA), do occur. Recently, attention has been focused on molecular targeted...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764050/ https://www.ncbi.nlm.nih.gov/pubmed/31598607 http://dx.doi.org/10.1177/2632010X19873384 |
_version_ | 1783454295455170560 |
---|---|
author | de Souza, Ana Amélia Altemani, Albina de Araujo, Ney Soares Texeira, Lucas Novaes de Araújo, Vera Cavalcanti Soares, Andresa Borges |
author_facet | de Souza, Ana Amélia Altemani, Albina de Araujo, Ney Soares Texeira, Lucas Novaes de Araújo, Vera Cavalcanti Soares, Andresa Borges |
author_sort | de Souza, Ana Amélia |
collection | PubMed |
description | Pleomorphic adenoma (PA) is the most common salivary gland neoplasm and, although mostly benign, recurrences, being called recurrent pleomorphic adenoma (RPA) and malignant transformation to carcinoma ex pleomorphic adenoma (CXPA), do occur. Recently, attention has been focused on molecular targeted cancer therapy in various tumors, including salivary gland tumors. The aim of this study was to investigate the role of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) in PA, RPA, and CXPA. In total, 20 cases of PA, 18 of RPA, and 7 cases of CXPA were immunohistochemically studied for ER, PR, and HER-2. For evaluation of ER and PR, only nuclear expression and greater than 10% positive cells were regarded as cutoff criteria. HER-2 was evaluated semiquantitatively and graded from 0 to 3+. HER-2 amplification was assessed by chromogenic in situ hybridization (CISH). Tumors were negative for ER, PR, and HER-2 in all cases of PA and RPA. A case of CXPA showed moderate and complete membranous staining, and 6 cases were negative. HER-2 amplification was not observed in any case. In conclusion, the lack of ER, PR, and HER-2 expression in PA, RPA, and CXPA suggests that these proteins are not involved in progression, recurrence, or malignant transformation of PA. |
format | Online Article Text |
id | pubmed-6764050 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-67640502019-10-09 Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma de Souza, Ana Amélia Altemani, Albina de Araujo, Ney Soares Texeira, Lucas Novaes de Araújo, Vera Cavalcanti Soares, Andresa Borges Clin Pathol Brief Report Pleomorphic adenoma (PA) is the most common salivary gland neoplasm and, although mostly benign, recurrences, being called recurrent pleomorphic adenoma (RPA) and malignant transformation to carcinoma ex pleomorphic adenoma (CXPA), do occur. Recently, attention has been focused on molecular targeted cancer therapy in various tumors, including salivary gland tumors. The aim of this study was to investigate the role of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) in PA, RPA, and CXPA. In total, 20 cases of PA, 18 of RPA, and 7 cases of CXPA were immunohistochemically studied for ER, PR, and HER-2. For evaluation of ER and PR, only nuclear expression and greater than 10% positive cells were regarded as cutoff criteria. HER-2 was evaluated semiquantitatively and graded from 0 to 3+. HER-2 amplification was assessed by chromogenic in situ hybridization (CISH). Tumors were negative for ER, PR, and HER-2 in all cases of PA and RPA. A case of CXPA showed moderate and complete membranous staining, and 6 cases were negative. HER-2 amplification was not observed in any case. In conclusion, the lack of ER, PR, and HER-2 expression in PA, RPA, and CXPA suggests that these proteins are not involved in progression, recurrence, or malignant transformation of PA. SAGE Publications 2019-09-26 /pmc/articles/PMC6764050/ /pubmed/31598607 http://dx.doi.org/10.1177/2632010X19873384 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Brief Report de Souza, Ana Amélia Altemani, Albina de Araujo, Ney Soares Texeira, Lucas Novaes de Araújo, Vera Cavalcanti Soares, Andresa Borges Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma |
title | Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in
Recurrent Pleomorphic Adenoma |
title_full | Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in
Recurrent Pleomorphic Adenoma |
title_fullStr | Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in
Recurrent Pleomorphic Adenoma |
title_full_unstemmed | Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in
Recurrent Pleomorphic Adenoma |
title_short | Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in
Recurrent Pleomorphic Adenoma |
title_sort | estrogen receptor, progesterone receptor, and her-2 expression in
recurrent pleomorphic adenoma |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764050/ https://www.ncbi.nlm.nih.gov/pubmed/31598607 http://dx.doi.org/10.1177/2632010X19873384 |
work_keys_str_mv | AT desouzaanaamelia estrogenreceptorprogesteronereceptorandher2expressioninrecurrentpleomorphicadenoma AT altemanialbina estrogenreceptorprogesteronereceptorandher2expressioninrecurrentpleomorphicadenoma AT dearaujoneysoares estrogenreceptorprogesteronereceptorandher2expressioninrecurrentpleomorphicadenoma AT texeiralucasnovaes estrogenreceptorprogesteronereceptorandher2expressioninrecurrentpleomorphicadenoma AT dearaujoveracavalcanti estrogenreceptorprogesteronereceptorandher2expressioninrecurrentpleomorphicadenoma AT soaresandresaborges estrogenreceptorprogesteronereceptorandher2expressioninrecurrentpleomorphicadenoma |